Evidence map›Paper›PMID 31535451›Full record

ArticleEMBO reports2019

NPC1 enables cholesterol mobilization during long-term potentiation that can be restored in Niemann-Pick disease type C by CYP46A1 activation.

Daniel N Mitroi, Guadalupe Pereyra-Gómez, Beatriz Soto-Huelin, Fernando Senovilla, Toshihide Kobayashi, Jose A Esteban, María Dolores Ledesma

Open access · hybridAbstract read
In one paragraph

Article in EMBO reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 66 citations in OpenAlex.

  1. Efficacy and safety of efavirenz in Niemann-Pick disease type C.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Enhanced mGluRCell death & disease · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Oxysterols in Central and Peripheral Synaptic Communication.Advances in experimental medicine and biology · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Daniel N MitroiDepartment of Molecular Neuropathology, Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain.ORCID 0000-0001-5689-139X
Guadalupe Pereyra-GómezDepartment of Molecular Neuropathology, Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain.
Beatriz Soto-HuelinDepartment of Molecular Neuropathology, Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain.
Fernando SenovillaDepartment of Molecular Neuropathology, Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain.
Toshihide KobayashiLaboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France.
Jose A EstebanDepartment of Molecular Neuropathology, Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain.
María Dolores LedesmaDepartment of Molecular Neuropathology, Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain.ORCID 0000-0002-5679-6891
Centro de Biología Molecular Severo Ochoa · ESLaboratoire de Biophotonique et Pharmacologie · FR

Funding

Fundación Alicia KoplowitzFundación Niemann Pick EspañaFundación Ramón ArecesMinisterio Economía, Industria y Competitividad SAF2017-87698-R (AEI/FEDER UE)University of Bonn, Germany
6 · The paper itself

Abstract

NPC is a neurodegenerative disorder characterized by cholesterol accumulation in endolysosomal compartments. It is caused by mutations in the gene encoding NPC1, an endolysosomal protein mediating intracellular cholesterol trafficking. Cognitive and psychiatric alterations are hallmarks in NPC patients pointing to synaptic defects. However, the role of NPC1 in synapses has not been explored. We show that NPC1 is present in the postsynaptic compartment and is locally translated during LTP. A mutation in a region of the NPC1 gene commonly altered in NPC patients reduces NPC1 levels at synapses due to enhanced NPC1 protein degradation. This leads to shorter postsynaptic densities, increased synaptic cholesterol and impaired LTP in NPC1

Indexed as

Long-Term PotentiationAnimalsCholesterolCholesterol 24-HydroxylaseDisease Models, AnimalHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsMiceMice, KnockoutModels, BiologicalNiemann-Pick C1 ProteinNiemann-Pick Disease, Type CProtein BiosynthesisReceptors, AMPASynapsesCholesterolCholesterol 24-HydroxylaseIntracellular Signaling Peptides and ProteinsNiemann-Pick C1 ProteinNPC1 protein, humanReceptors, AMPAcholesterolCYP46A1EfavirenzNPC1synaptic plasticity

Identifiers

PMID31535451
PMCPMC6832102
OpenAlexW2974923184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.